| Article 197 |
Heart Attack Patients Are Not Taking Statins
Future heart events such as heart attack, cardiovascular diseases and stroke can be prevented by taking high doses of statin drugs. But a study shows a number of patients with a risk of heart diseases are not taking the recommended statin drugs.
The two-year follow-up study was done on 30,000 Medicare patients with heart attack, aged between 66 and 75 years. All the participants have received the prescription of high-intensity statins during hospitalization from a heart attack or stroke. The follow-up study has found the following.
- Just 42 percent of the heart patients are taking statin medications regularly.
- Just 13 percent of the heart patients are taking a low or moderate intensity or doses of statins even though they are advised to take high intensity or doses of statin drugs.
- About 19 percent of the heart patients are not taking statin medication regularly.
- Nearly 20 percent of the heart patients stopped taking medication.
As the use of a statin drug can prevent future risk associated with stroke and heart attacks, heart patients should continue using them with a drug dosage prescribed by the physician.
The lead author of the study was Professor Robert Rosenson, Icahn School of Medicine, Mount Sinai, New York City and the study was published on April 19, 2017, in JAMA Cardiology. Title of the article is "Adherence to High-Intensity Statins Following a Myocardial Infarction Hospitalization Among Medicare Beneficiaries."
The drug Canagliflozin (Invokana) Shows An Improvement In The Metabolic Function, HbA1c And Leptin
Canagliflozin (marketed as Invokana) is an SGLT2 inhibitor for the treatment of type 2 diabetes (T2D).
In ongoing research at the University of Alabama, Birmingham shows the reduction in the function of adipose tissue (fat) with canagliflozin compared with glimepiride.
The reduction in the function of adipose tissue (fat) is independent of weight loss. The reduction in the adipose tissue can cause a big impact on the change in energy balance and body metabolism.
In the CANVAS study on two groups of adult patients with type 2 diabetes, one group of patients is being treated with 300 mg of canagliflozin daily for 52 weeks. Similarly, another group of patients is being treated with glimepiride (marketed under the trade name Amaryl).
The study has analyzed the samples for a change in the body weight, HbA1c levels and the function of adipose tissue (fat).
At the end of 52 weeks, the researchers have observed the following in the group of patients taking canagliflozin (marketed as Invokana) compared with the group of patients taking the antidiabetic drug, glimepiride.
- Greater reduction in HbA1c levels.
- Greater body weight loss.
- An improvement in the metabolic function.
- Reduction in leptin, a hormone which causes hunger.
The lead author of the study is Timothy W Garvey, MD and the study was presented at the American Association of Clinical Endocrinologists (AACE), 26th Annual Scientific and Clinical Congress 2017, Austin, Texas, United States. The final results will be declared after the completion of the CANVAS study.
Glimepiride: Some patients of type 2 diabetes (T2D) could not lower blood sugar levels with diet and physical exercise. Glimepiride (an oral sulfonylurea antidiabetic medicine) is used to reduce blood sugar (glucose) levels of the patients by triggering the pancreas to release insulin.
Adipose tissue: Adipose tissue function is to store excess calories in the form of fat under the skin, around internal organs, breast tissue and bone marrow. The adipose tissue insulates the body too. But, the function of adipose tissue will be weakened in obese people, a risk factor to type 2 diabetes (T2D).
| Published on May 26, 2017 |
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.